Q6A068
PR
Gene name |
Cdc5l (Kiaa0432) |
Protein name |
Cell division cycle 5-like protein |
Names |
Cdc5-like protein |
Species |
Mus musculus (Mouse) |
KEGG Pathway |
mmu:71702 |
EC number |
|
Protein Class |
|
Descriptions
The autoinhibited protein was predicted that may have potential autoinhibitory elements via cis-regPred.
Autoinhibitory domains (AIDs)
Target domain |
|
Relief mechanism |
|
Assay |
cis-regPred |
Accessory elements
No accessory elements
Autoinhibited structure
Activated structure
1 structures for Q6A068
| Entry ID | Method | Resolution | Chain | Position | Source |
|---|---|---|---|---|---|
| AF-Q6A068-F1 | Predicted | AlphaFoldDB |
75 variants for Q6A068
| Variant ID(s) | Position | Change | Description | Diseaes Association | Provenance |
|---|---|---|---|---|---|
| rs386938012 | 80 | T>K | No | EVA | |
| rs387656344 | 87 | P>L | No | EVA | |
| rs1132121961 | 87 | P>T | No | EVA | |
| rs1134970182 | 90 | G>E | No | EVA | |
| rs1132999898 | 91 | R>K | No | EVA | |
| rs3389480520 | 103 | L>I | No | EVA | |
| rs3389464823 | 104 | L>Q | No | EVA | |
| rs3389480484 | 121 | R>P | No | EVA | |
| rs3389459840 | 167 | A>D | No | EVA | |
| rs1134776425 | 189 | R>Q | No | EVA | |
| rs1133756679 | 199 | Q>* | No | EVA | |
| rs247299179 | 208 | V>F | No | EVA | |
| rs247299179 | 208 | V>I | No | EVA | |
| rs1131963207 | 217 | E>D | No | EVA | |
| rs1135267478 | 222 | L>P | No | EVA | |
| rs3389465259 | 240 | R>M | No | EVA | |
| rs3389433909 | 241 | K>R | No | EVA | |
| rs3389444641 | 326 | E>A | No | EVA | |
| rs1134975473 | 373 | T>I | No | EVA | |
| rs1133013084 | 377 | T>I | No | EVA | |
| rs1132462205 | 378 | P>L | No | EVA | |
| rs1133188670 | 385 | T>I | No | EVA | |
| rs1133347079 | 389 | E>* | No | EVA | |
| rs1134070439 | 394 | G>D | No | EVA | |
| rs3389377382 | 425 | P>L | No | EVA | |
| rs3411998036 | 442 | T>R | No | EVA | |
| rs3389480472 | 514 | D>V | No | EVA | |
| rs3389433922 | 555 | I>N | No | EVA | |
| rs3410966518 | 562 | E>G | No | EVA | |
| rs3389459891 | 578 | E>* | No | EVA | |
| rs1132610498 | 579 | M>L | No | EVA | |
| rs1132872761 | 581 | T>A | No | EVA | |
| rs1133595582 | 581 | T>M | No | EVA | |
| rs3389459594 | 583 | L>F | No | EVA | |
| rs1134242532 | 585 | Y>S | No | EVA | |
| rs1134238147 | 593 | E>K | No | EVA | |
| rs1134393715 | 598 | K>* | No | EVA | |
| rs218582355 | 605 | F>L | No | EVA | |
| rs1133019848 | 607 | T>A | No | EVA | |
| rs1132164239 | 608 | N>I | No | EVA | |
| rs1133356779 | 609 | N>I | No | EVA | |
| rs1133511962 | 611 | E>K | No | EVA | |
| rs1132701005 | 619 | S>R | No | EVA | |
| rs1132151030 | 623 | K>T | No | EVA | |
| rs3408055335 | 626 | K>* | No | EVA | |
| rs3389476312 | 636 | L>P | No | EVA | |
| rs3389476312 | 636 | L>R | No | EVA | |
| rs3389463784 | 638 | Q>* | No | EVA | |
| rs3389463784 | 638 | Q>K | No | EVA | |
| rs3389480481 | 640 | M>I | No | EVA | |
| rs3389377380 | 642 | V>M | No | EVA | |
| rs3389476370 | 650 | G>V | No | EVA | |
| rs3389464845 | 664 | C>S | No | EVA | |
| rs3389414487 | 702 | H>Q | No | EVA | |
| rs1131985875 | 711 | A>E | No | EVA | |
| rs3389455950 | 714 | E>V | No | EVA | |
| rs1132709474 | 715 | K>M | No | EVA | |
| rs1133039627 | 719 | I>N | No | EVA | |
| rs1133039627 | 719 | I>S | No | EVA | |
| rs1133039627 | 719 | I>T | No | EVA | |
| rs1133765281 | 720 | L>M | No | EVA | |
| rs3389480502 | 721 | L>I | No | EVA | |
| rs1134497281 | 727 | R>H | No | EVA | |
| rs3389463811 | 728 | A>V | No | EVA | |
| rs1133931785 | 750 | R>C | No | EVA | |
| rs3389377384 | 750 | R>P | No | EVA | |
| rs1134661191 | 776 | R>Q | No | EVA | |
| rs3389433905 | 776 | R>W | No | EVA | |
| rs1134081364 | 778 | Q>R | No | EVA | |
| rs1134245086 | 780 | R>* | No | EVA | |
| rs1131830465 | 783 | E>K | No | EVA | |
| rs1133030278 | 789 | A>S | No | EVA | |
| rs1135154967 | 789 | A>V | No | EVA | |
| rs3389476305 | 793 | M>I | No | EVA | |
| rs1133514347 | 800 | A>V | No | EVA |
No associated diseases with Q6A068
11 GO annotations of cellular component
| Name | Definition |
|---|---|
| catalytic step 2 spliceosome | A spliceosomal complex that contains three snRNPs, including U5, bound to a splicing intermediate in which the first catalytic cleavage of the 5' splice site has occurred. The precise subunit composition differs significantly from that of the catalytic step 1, or activated, spliceosome, and includes many proteins in addition to those found in the associated snRNPs. |
| cytoplasm | The contents of a cell excluding the plasma membrane and nucleus, but including other subcellular structures. |
| DNA replication factor A complex | A conserved heterotrimeric complex that binds nonspecifically to single-stranded DNA and is required for multiple processes in eukaryotic DNA metabolism, including DNA replication, DNA repair, and recombination. In all eukaryotic organisms examined the complex is composed of subunits of approximately 70, 30, and 14 kDa. |
| nuclear speck | A discrete extra-nucleolar subnuclear domain, 20-50 in number, in which splicing factors are seen to be localized by immunofluorescence microscopy. |
| nucleoplasm | That part of the nuclear content other than the chromosomes or the nucleolus. |
| nucleus | A membrane-bounded organelle of eukaryotic cells in which chromosomes are housed and replicated. In most cells, the nucleus contains all of the cell's chromosomes except the organellar chromosomes, and is the site of RNA synthesis and processing. In some species, or in specialized cell types, RNA metabolism or DNA replication may be absent. |
| perinuclear region of cytoplasm | Cytoplasm situated near, or occurring around, the nucleus. |
| protein-DNA complex | A macromolecular complex containing both protein and DNA molecules. |
| Prp19 complex | A protein complex consisting of Prp19 and associated proteins that is involved in the transition from the precatalytic spliceosome to the activated form that catalyzes step 1 of splicing, and which remains associated with the spliceosome through the second catalytic step. It is widely conserved, found in both yeast and mammals, though the exact composition varies. In S. cerevisiae, it contains Prp19p, Ntc20p, Snt309p, Isy1p, Syf2p, Cwc2p, Prp46p, Clf1p, Cef1p, and Syf1p. |
| spliceosomal complex | Any of a series of ribonucleoprotein complexes that contain snRNA(s) and small nuclear ribonucleoproteins (snRNPs), and are formed sequentially during the spliceosomal splicing of one or more substrate RNAs, and which also contain the RNA substrate(s) from the initial target RNAs of splicing, the splicing intermediate RNA(s), to the final RNA products. During cis-splicing, the initial target RNA is a single, contiguous RNA transcript, whether mRNA, snoRNA, etc., and the released products are a spliced RNA and an excised intron, generally as a lariat structure. During trans-splicing, there are two initial substrate RNAs, the spliced leader RNA and a pre-mRNA. |
| U2-type catalytic step 2 spliceosome | A spliceosomal complex that contains the U2, U5 and U6 snRNPs bound to a splicing intermediate in which the first catalytic cleavage of the 5' splice site has occurred. The precise subunit composition differs significantly from that of the catalytic step 1, or activated, spliceosome, and includes many proteins in addition to those found in the U2, U5 and U6 snRNPs. |
10 GO annotations of molecular function
| Name | Definition |
|---|---|
| DNA-binding transcription activator activity, RNA polymerase II-specific | A DNA-binding transcription factor activity that activates or increases transcription of specific gene sets transcribed by RNA polymerase II. |
| DNA-binding transcription factor activity, RNA polymerase II-specific | A DNA-binding transcription factor activity that modulates the transcription of specific gene sets transcribed by RNA polymerase II. |
| identical protein binding | Binding to an identical protein or proteins. |
| leucine zipper domain binding | Binding to a leucine zipper domain, a protein secondary structure exhibiting a periodic repetition of leucine residues at every seventh position over a distance covering eight helical turns. |
| protein kinase binding | Binding to a protein kinase, any enzyme that catalyzes the transfer of a phosphate group, usually from ATP, to a protein substrate. |
| protein phosphatase 1 binding | Binding to a protein phosphatase 1. |
| RNA binding | Binding to an RNA molecule or a portion thereof. |
| RNA polymerase II transcription regulatory region sequence-specific DNA binding | Binding to a specific sequence of DNA that is part of a regulatory region that controls the transcription of a gene or cistron by RNA polymerase II. |
| transcription corepressor binding | Binding to a transcription corepressor, a protein involved in negative regulation of transcription via protein-protein interactions with transcription factors and other proteins that negatively regulate transcription. Transcription corepressors do not bind DNA directly, but rather mediate protein-protein interactions between repressing transcription factors and the basal transcription machinery. |
| WD40-repeat domain binding | Binding to a WD40 repeat domain of a protein. The WD40 repeat is a short structural motif of approximately 40 amino acids, often terminating in a tryptophan-aspartic acid (W-D) dipeptide. Several of these repeats are combined to form a type of protein domain called the WD domain. |
8 GO annotations of biological process
| Name | Definition |
|---|---|
| cellular response to nerve growth factor stimulus | A process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a nerve growth factor stimulus. |
| cellular response to wortmannin | Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a wortmannin stimulus. |
| DNA damage checkpoint signaling | A signal transduction process that contributes to a DNA damage checkpoint. |
| DNA repair | The process of restoring DNA after damage. Genomes are subject to damage by chemical and physical agents in the environment (e.g. UV and ionizing radiations, chemical mutagens, fungal and bacterial toxins, etc.) and by free radicals or alkylating agents endogenously generated in metabolism. DNA is also damaged because of errors during its replication. A variety of different DNA repair pathways have been reported that include direct reversal, base excision repair, nucleotide excision repair, photoreactivation, bypass, double-strand break repair pathway, and mismatch repair pathway. |
| mitotic cell cycle | Progression through the phases of the mitotic cell cycle, the most common eukaryotic cell cycle, which canonically comprises four successive phases called G1, S, G2, and M and includes replication of the genome and the subsequent segregation of chromosomes into daughter cells. In some variant cell cycles nuclear replication or nuclear division may not be followed by cell division, or G1 and G2 phases may be absent. |
| mRNA splicing, via spliceosome | The joining together of exons from one or more primary transcripts of messenger RNA (mRNA) and the excision of intron sequences, via a spliceosomal mechanism, so that mRNA consisting only of the joined exons is produced. |
| positive regulation of transcription by RNA polymerase II | Any process that activates or increases the frequency, rate or extent of transcription from an RNA polymerase II promoter. |
| regulation of transcription by RNA polymerase II | Any process that modulates the frequency, rate or extent of transcription mediated by RNA polymerase II. |
| 10 | 20 | 30 | 40 | 50 | 60 |
| MPRIMIKGGV | WRNTEDEILK | AAVMKYGKNQ | WSRIASLLHR | KSAKQCKARW | YEWLDPSIKK |
| 70 | 80 | 90 | 100 | 110 | 120 |
| TEWSREEEEK | LLHLAKLMPT | QWRTIAPIIG | RTAAQCLEHY | EFLLDKTAQR | DNEEETTDDP |
| 130 | 140 | 150 | 160 | 170 | 180 |
| RKLKPGEIDP | NPETKPARPD | PIDMDEDELE | MLSEARARLA | NTQGKKAKRK | AREKQLEEAR |
| 190 | 200 | 210 | 220 | 230 | 240 |
| RLAALQKRRE | LRAAGIEIQK | KRKKKRGVDY | NAEIPFEKKP | ALGFYDTSEE | NYQALDADFR |
| 250 | 260 | 270 | 280 | 290 | 300 |
| KLRQQDLDGE | LRSEKEGRDR | KKDKQHLKRK | KESDLPSAIL | QTSGVSEFTK | KRSKLVLPAP |
| 310 | 320 | 330 | 340 | 350 | 360 |
| QISDAELQEV | VKVGQASEVA | RQTAEESGIT | NSASSTLLSE | YNVTNNSIAL | RTPRTPASQD |
| 370 | 380 | 390 | 400 | 410 | 420 |
| RILQEAQNLM | ALTNVDTPLK | GGLNTPLHES | DFSGVTPQRQ | VVQTPNTVLS | TPFRTPSNGA |
| 430 | 440 | 450 | 460 | 470 | 480 |
| EGLTPRSGTT | PKPVTNATPG | RTPLRDKLNI | NPEDGMADYS | DPSYVKQMER | ESREHLRLGL |
| 490 | 500 | 510 | 520 | 530 | 540 |
| LGLPAPKNDF | EIVLPENAEK | ELEEREIDDT | YIEDAADVDA | RKQAIRDAER | VKEMKRMHKA |
| 550 | 560 | 570 | 580 | 590 | 600 |
| VQKDLPRPSE | VNETILRPLN | VEPPLTDLQK | SEELIKKEMI | TMLHYDLLHH | PYEPSGNKKG |
| 610 | 620 | 630 | 640 | 650 | 660 |
| KNVGFATNNS | EHITYLEHSP | YEKFSKEDLK | KAQDALVQEM | EVVKQGMSHG | ELSSEAYNQV |
| 670 | 680 | 690 | 700 | 710 | 720 |
| WEECYSQVLY | LPAQSRYTRA | NLASKKDRIE | SLEKRLEINR | GHMTTEAKRA | AKMEKKMKIL |
| 730 | 740 | 750 | 760 | 770 | 780 |
| LGGYQSRAMG | LMKQLNDLWD | QIEQAHLELR | TFEELKKHED | SAIPRRLECL | KEDVQRQQER |
| 790 | 800 | ||||
| EKELQQRYAD | LLMEKETLQA | KF |